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a  b  s  t  r  a  c  t
PspA  and pneumolysin  (Ply)  are  important  protein  vaccine  candidates.  HIV infection  is  associated  with
increased  susceptibility  to pneumococcal  pneumonia  and  concomitantly  high pneumococcal  carriage
rates.  Pneumococcal  exposure  is immunizing  at the mucosa  in healthy  adults  and so  we  wished  to  deter-
mine  if the increased  pneumococcal  exposure  in  HIV-infected  adults  would  be associated  with  altered
pneumococcal  speciﬁc  antibody  responses.  We  measured  serum  and  bronchoalveolar  lavage (BAL)  ﬂuid
immunoglobulin  (Ig)G and IgA  to PspA  and  Ply in  HIV-infected  and healthy  age-matched  adults.





infected  subjects  in  BAL  independent  of  the  hyperglobulinaemia  commonly  associated  with  HIV.  There
was therefore  no evidence  of a defect  in mucosal  responses  to pneumococcal  protein  antigens  among
HIV-infected  adults.
With  regard  to future  vaccination  strategies,  simply  increasing  mucosal  anti-pneumococcal  protein
Ig levels,  without  addressing  functional  protective  response,  is not  likely  to be  effective  in preventing
a  in Hpneumococcal  pneumoni
. Introduction
Streptococcus pneumoniae is the most common cause of com-
unity acquired pneumonia in both HIV-infected and non-HIV
nfected individuals [1]. The rate of invasive pneumococcal disease
IPD) in HIV-infected individuals is 40–100 times greater than age-
atched controls, due to several immune defects including low
D4 T-cell numbers and impairment of the humoral response [2].
he factors underlying the susceptibility of HIV-infected patients
o pneumococcal pneumonia remain poorly understood.
Despite the fact that the 7-valent pneumococcal conjugate
accine (PCV) has shown up to 75% protection against recurrent
PD from vaccine serotypes in HIV-infected individuals [3], alter-
ative protective strategies including protein vaccines remain
n important worldwide priority, due to serotype-replacement,
 lack of longevity of effect and an unclear protection against
neumonia.
Pneumococcal surface protein A (PspA) and pneumolysin (Ply)
re leading protein vaccine candidates able to confer protection
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against pneumonia and invasive disease in murine models [4].
Antibodies to PspA and Ply appear early in life and the increase
of antigen-speciﬁc IgA and IgG levels with age suggests a role for
these responses in the prevention of IPD [5]. Moreover, coloniza-
tion in children and healthy adults elicited antibody responses to
both antigens [6,7].
HIV-infected African adults have high rates of pneumococcal
colonization and a persistently poor control of pneumococcal col-
onization [8]. Frequent carriage is likely to be associated with
repeated antigenic stimulation and therefore high antibody levels.
We tested the hypothesis that pneumococcal protein-speciﬁc (PspA
and Ply) responses would be altered in HIV-infected patients and
would be either elevated due to increased rates of pneumococcal
carriage and disease, or reduced due to their immunocompromised
state. We also postulated that the response would be compart-
mentalized and mucosal and serum antibody levels would be
independently regulated.
We have previously reported higher levels of serum anti-Ply
in HIV-infected patients compared to HIV-non infected controls
[9]. High levels of anti-pneumolysin IgG did not predict protection
from invasive pneumococcal disease or indicate that an effective
immune response has occurred in HIV infected patients. Others
Open access under CC BY license. have reported that impaired immunity to Ply was associated with
a higher incidence of pneumococcal bacteraemia in HIV-infected
patients [10]. Levels of speciﬁc anti-pneumococcal protein IgG and
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We  have now measured anti-PspA and anti-Ply IgG and IgA
n the lung and serum of HIV-infected patients and an HIV-non
nfected control group.
. Subjects and methods
.1. Patient selection and HIV testing
50 volunteers were recruited after obtaining fully informed
ritten consent at the Queen Elizabeth Central Hospital, Blantyre,
alawi. No volunteer had any history of previous pneumococcal
isease or vaccination. The study was given ethical approval by the
iverpool School of Tropical Medicine and the College of Medicine
University of Malawi) Research Ethics Committees. HIV status was
etermined by HIV gold and HIV serocard: Trinity Biotech and
LISA. All subjects were asymptomatic (normal physical examina-
ion and chest radiograph).
.2. Bronchoscopy and bronchoalveolar lavage (BAL)
Bronchoscopy and BAL were performed as previously described
11] using 200 ml  of warm saline. After centrifugation at 330 g for
0 min  BAL supernatant was transferred into 50 ml  centrifuge tubes
nd stored at–80 ◦C before ELISA testing.
.3. ELISA measurement of Ig levels
ELISA assays were performed to determine total IgG and pneu-
ococcal speciﬁc IgG and IgA as previously described by our group
11,12]. Microplates (NUNC) were coated with Goat anti-human IgG
Dako) for total IgG or 2 g/ml of PspA or Ply for pneumococcal spe-
iﬁc IgG. Serial diluted samples and a standard sample with known
oncentration of total IgG were added in duplicate. Antibody detec-
ion was performed by goat anti-human IgG or IgA biotinylated
ntibody followed by streptavidin alkaline phosphatase antibody
Oxford Biotechnology). 0.5 mg/ml  of p-nitrophenyl phosphate
PNPP) (Sigma) was used for development. Absorbance was read
t 405 nm using a FLUOstar Omega (BMG Labtech). Results were
nalyzed using 4-parameter ﬁtted curve and samples that showed
V > 15% were repeated.
ig. 1. Pneumococcal speciﬁc Ig concentrations in bronchoalveolar lavage (BAL) of HIV-
f  values and 95% conﬁdence intervals. Anti-Ply IgG (a), Anti-Ply IgA (b), Anti-PspA IgG (c
g/ml.  *Statistical signiﬁcance using unpaired Student’s t-test (p < 0.05).1 (2013) 3469– 3472
2.4. Statistical analysis
Mean and 95% conﬁdence intervals of Ig levels are presented
at the graphs and log transformed data was  used for statisti-
cal analysis. Ratios of pneumococcal speciﬁc IgG to total IgG
were calculated on log transformed data. Unpaired Student t-test
was used to compare levels between HIV-infected and control
groups. Pearson’s r test was  used to analyze correlation between
BAL and serum concentrations. p ≤ 0.05 was considered statistical
signiﬁcant.
3. Results
25 HIV-infected and 25 HIV negative (age and sex matched)
volunteers were recruited. No volunteers were receiving highly
active anti-retroviral therapy (HAART). The median CD4 count was
340 cells/mm3 in the HIV-infected and 785 cells/mm3 in the HIV
negative subjects. The BAL volume yield ranged from 72 to 148 ml.
No serious adverse events related to the research bronchoscopy
were observed.
We  observed that anti-Ply and anti-PspA IgG levels in BAL
were signiﬁcantly higher in the HIV-infected subjects compared
to the control subjects (p < 0.0001) (Fig. 1a and c). No difference
was observed for anti-Ply and anti-PspA IgA levels in BAL (Fig. 1b
and d). We  measured total IgG in BAL and also expressed anti-
Ply and anti-PspA IgG levels as ratios of total IgG (Table 1). The
HIV-infected group had higher total IgG levels than the control
group (mean, 95%CI; 13,404 ng/ml, 6985–19823 vs 4400 ng/ml,
3254–5546, p = 0.003 using un-paired t-test). Higher ratios of pneu-
mococcal speciﬁc IgG to both antigens were observed in BAL of
HIV-infected subjects than control group (For Ply: 0.18, 0.13–0.23
vs 0.05, 0.007–0.09, p = 0.0003 and for PspA: 0.36, 0.31–0.41 vs 0.27,
0.23–0.30, p = 0.001).
The HIV-infected group also showed increased serum anti-Ply
IgG (p = 0.0007) and IgA (p = 0.02) (Fig. 2a and b) slightly increased
anti-PspA IgA (p = 0.05, Fig. 2d) but no increase in anti-PspA IgG
(p = 0.22, Fig. 2c).
Anti-Ply and Anti-PspA IgG and IgA levels were much lower in
BAL than serum in all subjects; even considering the dilution of BAL
samples (diluted 60–100-fold during collection).
infected and control groups. Each plot represents a subject and bars are the mean
) and Anti-PspA IgA (d), levels of HIV-infected and control groups are expressed in
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Table 1
BAL levels of total IgG, anti-pneumococcal speciﬁc IgG and ratios of pneumococcal speciﬁc IgG: total IgG in HIV-infected and control groups.
HIV-infected Control p-Value
Total IgG 13,404 (6985, 19,823) 4400 (3254, 5546) 0.003a
Anti-Ply IgG 9.83 (2.70, 16.97) 2.19 (1.40, 2.97) 0.02a
Anti-Ply:total IgG ratio 0.18 (0.13, 0.23) 0.05 (0.01, 0.09) 0.0002a
Anti-PspA IgG 45.66 (17.99, 73.34) 11.82 (8.49, 15.14) 0.01a
Anti-PspA:total IgG ratio 0.36 (0.31, 0.41) 0.27 (0.24, 0.30) 0.001a
Values are mean ± 95% conﬁdence intervals and ratios of pneumococcal speciﬁc IgG:total IgG.


























pig. 2. Pneumococcal speciﬁc Ig concentrations in serum of HIV-infected and control
ntervals. Anti-Ply IgG (a), Anti-Ply IgA (b), Anti-PspA IgG (c) and Anti-PspA IgA (d), 
sing  unpaired Student’s t-test (p < 0.05).
We  observed a generally poor correlation between BAL and
erum levels of anti-Ply IgG (HIV: r = −0.01, p = 0.92 and control:
 = 0.02, p = 0.89); anti-Ply IgA (HIV: r = 0.11, p = 0.59 and control:
 = −0.04, p = 0.81); anti-PspA IgG (HIV: r = −0.04, p = 0.83 and con-
rol: r = 024, p = 0.24) and anti-PspA IgA (control: r = 0.11, p = 0.59).
 statistical signiﬁcant correlation between BAL and serum was
bserved to anti-PspA IgA in HIV-infected subjects only (r = 0.41,
 = 0.03).
. Discussion
We  have shown that HIV-infected patients had higher levels of
neumococcal speciﬁc IgG (anti-Ply and anti-PspA) in BAL than lev-
ls measured in a control group. This effect may  be attributed to
olyclonal B-cell activation and hyperglobulinaemia but it is not
niform as we have demonstrated increased ratios of pneumococ-
al speciﬁc IgG in relation to total IgG in BAL.
Serum immunoglobulins (Ig) are critical in defence against inva-
ive disease and lung-lining ﬂuid Ig are critical in primary mucosal
efence, particularly to opsonophagocytosis of capsulate pneumo-
occi by alveolar macrophages [13].
In HIV infection there is poor correlation between total and
peciﬁc Ig levels in serum to encapsulated bacteria because of
he associated polyclonal B-cell activation [14]. The pulmonary
ucosal surface, however, does not exhibit the same immune
efects as does the systemic defence. Pulmonary mucosal Ig
esponses to protein antigen are locally regulated and independent
f serum IgG levels [15] with some mucosal immunity relatively
reserved, compared with systemic immunity [11,16].s. Each plot represents a subject and bars are the mean of values and 95% conﬁdence
 of HIV-infected and control groups are expressed in ng/ml. *Statistical signiﬁcance
In this study, a poor correlation was found between serum
and BAL pneumococcal speciﬁc Ig levels in both HIV-infected and
control groups. This suggests that local synthesis rather than tran-
sudation of antibody from serum into the alveoli is more likely to
be the cause of the increased pneumococcal-speciﬁc IgG in BAL.
Pneumococcal colonization of the upper airway may  lead to micro
aspiration of bacteria to the lungs leading to antigen uptake by
antigen-presenting cells and local production by mature memory
B cells in the lung [17].
The fact that we observed increased IgG but not IgA in the
lung of HIV-infected subjects is supported by our previous pub-
lished work showing that intra-nasal exposure to pneumococcus
increases pneumococcal speciﬁc IgG but not IgA in the lung of
healthy adults [12]. The absence of difference in IgA levels in this
study suggests that HIV infection does not directly alter IgA levels
and that increased carriage of pneumococci in HIV infected subjects
does also not increase BAL IgA. We  conclude that there is therefore
no lung defect in anti-protein IgA responses but rather there are
different roles in protection mediated by IgG and IgA in the lung
compartment.
HIV-infected African adults have increased risk of repeat
colonization [18], persistently poor control of pneumococcal col-
onization and as a result high rates of colonization compared to
non-infected adults [8]. We  propose that increased IgG responses
observed in BAL in the HIV-infected group are a consequence of
their higher rates of carriage and previous infection. The func-
tional signiﬁcance of this natural boosting effect as well as the
mechanism underlying the defective mucosal protection from
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igh anti-pneumococcal polysaccharide speciﬁc (PPS) Ig but deﬁ-
ient opsonophagocytic activity (OPA) function [19,20] in BAL of
IV-infected patients. Other explanations include mucosal T cell
esponses or loss of other local regulatory constraints due to the
IV infection.
To further understand the function of BAL anti-pneumococcal
rotein responses, future studies will require microbiological data
elated to episodes of documented carriage and disease. Functional
ssays should also be investigated although speciﬁc pneumococcal
rotein antigen OPA assays are not currently available. The humoral
esponse is however not the only factor involved in protection from
ucosal disease but part of an interplay of various immune mech-
nisms affected by HIV, including the critical role of CD4 TH17
ells.
In conclusion, this study reveals that speciﬁc anti-pneumococcal
rotein IgG and IgA levels are differentially regulated according to
ompartment and are maintained during HIV-infection. The impli-
ations of this study are that vaccination resulting only in increased
evels of anti-protein IgG is unlikely to be effective at preventing
neumococcal disease in HIV-infected adults.
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